At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Research Grants 30 show all


$1M
2013

$12M
2014

$44.2M
2015

$967.5K
2016

$1.3M
2018

Publications 2,091 show all

  • 149
    Thalidomide/analogs & derivatives
  • 67
    Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • 57
    Multiple Myeloma/drug therapy
  • 30
    Myelodysplastic Syndromes/drug therapy
  • 24
    Antineoplastic Agents/therapeutic use
  • 24
    Pancreatic Neoplasms/drug therapy
  • 21
    Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • 20
    Antineoplastic Agents/pharmacology
  • 19
    Leukemia, Myeloid, Acute/drug therapy
  • 18
    Psoriasis/drug therapy

Patents 4,747show all

  • 1,496
    A61K - Preparations for medical, dental, or toilet purposes
  • 756
    C07D - Heterocyclic compounds
  • 187
    Y02A - Technologies for adaptation to climate change
  • 165
    C12N - Microorganisms or enzymes
  • 150
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 148
    C07K - Peptides
  • 142
    C07C - Acyclic or carbocyclic compounds
  • 102
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 98
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 97
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 1,652show all

567Phase 2429Phase 3240Phase 1160Phase 1/Phase 2126N/A51Other

SEC Filings show all


262
8-K

75
10-Q

24
10-K

Contact Information

Warren, NJ
United States